2025
Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
Roessler N, Miszczyk M, Matsukawa A, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Rajwa P, Schuettfort V, Vetterlein M, Soeterik T, Fazekas T, Fisch M, Leapman M, Karakiewicz P, Shariat S. Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science 2025, 80: 48-56. PMID: 40994543, PMCID: PMC12454867, DOI: 10.1016/j.euros.2025.08.008.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerFunctional Assessment of Cancer Therapy-ProstateImpact of PARP inhibitorsCastration-resistant prostate cancerPARP inhibitorsProspective trialsProstate cancerHealth-related quality of lifeHealth-related qualityQuality of lifeFunctional Assessment of Cancer Therapy-Prostate total scoreMeta-analysisHigh riskMean differenceAdvanced prostate cancerPARP inhibitor treatmentClinically meaningful deteriorationClinically meaningful impactTime pointsFunctional assessmentHigh risk of biasSystematic reviewStandard of careClinically Meaningful ImprovementsLate time points
2024
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Allen J, Lin J, Basta I, Dysgaard T, Eggers C, Guptill J, Gwathmey K, Hewamadduma C, Hofman E, Hussain Y, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu M, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis R, van Doorn P, Grinzinger S, Wanschitz J, Seifert-Held T, Claeys K, Baets J, Remiche G, Bissay V, Dubuisson N, Delstanche S, Tarnev I, Genov K, Tsvetanov P, Milanov I, Zhao C, Bu B, Yu X, Li W, Jiang H, Da Y, Lu Z, Liang H, Guo F, Li Z, Zou Z, Hong D, Yang H, Guo J, Shi J, Tu J, He D, Wang Y, Ding J, Zhang Y, Zhao Y, Xu R, Yue Y, Guo A, Wang Y, Talab R, Harbo T, Sindrup S, De Seze J, Sacconi S, Péréon Y, Echaniz-Laguna A, Magy L, Nicolas G, Taithe F, Cassereau J, Debs R, Shakarishvili R, Tsiskaridze A, Mania M, Janelidze M, Janelidze T, Schroeter M, Skripuletz T, Lee D, Klehmet J, Hotter B, Hoffmann O, Baum P, Zschuentzsch J, Pitarokoili K, Stettner M, Bereczki D, Pánczél G, Abraham A, Dori A, Lampl Y, Manganelli F, Morino S, Padovani A, Siciliano G, Schenone A, Magri F, Mazzeo A, Giannini F, Sorbi S, Chiò A, Kuwahara M, Okuno T, Okamoto T, Kokubun N, Nishiyama K, Kaida K, Bokuda K, Katsuno M, Yabe I, Saji E, Yokota T, Hatanaka Y, Nakahara J, Sugimoto T, Tanaka F, Tomita S, Yamano Y, Hayashi T, Yamazaki H, Tokashiki T, Horiuchi K, Karelis G, Eftimov F, Banach M, Chyrchel-Paszkiewicz U, Kochanowicz J, Selmaj K, Zielinski T, Banaszkiewicz K, Mitrea D, Scutaru-Kadar A, Axelerad A, Stuchevskaya F, Boyko A, Khabirov F, Trushnikova T, Goncharova Z, Suponeva N, Dorogov N, Yakupov E, Raicevic R, Miletic Drakulic S, Cabrera Serrano M, Muñoz Blanco J, Guerrero Sola A, Aguera Morales E, Diaz Marin C, Juntas Morales R, Yeh J, Sung J, Huang H, Tsai N, Guo Y, Chao C, Ro L, Sengun I, Terzi M, Alpaydin Baslo S, Koç F, Necdet Karli H, Shulga O, Smolko D, Doroshenko O, Tomakh N, Kyrychenko A, Seliuk O, Kalbus O, Skrypchenko I, Novakovska O, Carod-Artal F, Rinaldi S, Brennan K, Ellis S, Carr A, Matthews E, Traub R, Mozaffar T, Elliott M, Bhavaraju-Sanka R, Nance C, Levine T, Lisak R, Pasnoor M, Pulley M, Roy B, Govindarajan R, Sahagian G, Khella S, Jacob D, Kushlaf H, Sivakumar K, Melamed I, Sharma K, Quick A, Ubogu E, Lacomis D, Isa A, Brannagan T, Chen S, Katz J, Feinberg M, Pavlakis P, Lange D, Gudesblatt M, Tandan R, Gable K, Rivner M, Barnes B, Luke D, Mahuwala Z, Macwan S, Kwon P, Scott J, Altamimi S, Sabharwal P. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology 2024, 23: 1013-1024. PMID: 39304241, DOI: 10.1016/s1474-4422(24)00309-0.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsChronic inflammatory demyelinating polyradiculoneuropathyRisk of relapseInflammatory demyelinating polyradiculoneuropathyStage BStage ADouble-blindModified intention-to-treat populationIntention-to-treat populationOpen-label phaseInflammatory Neuropathy CauseInteractive response technologyPhase 2 trialPlacebo-controlled trialEvidence of clinical improvementClinically meaningful deteriorationPeripheral nervous systemPartial responseSafety populationPlacebo groupPlacebo-ControlledResidual neurological impairmentClinical improvementWeeks treatmentTreatment options
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply